NCT07748000 — "A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks" trial site landscape

Public-registry site landscape for NCT07748000, “A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks”, a Raynaud's Phenomenon Secondary to Systemic Sclerosis study sponsored by Liquidia Technologies, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07748000 (registry record)
Study title	A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks
Official title	A Phase 2a Randomized, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of LIQ861 in Participants With Systemic Sclerosis Experiencing Symptomatic Raynaud's Phenomenon Attacks / RE-WARM
Sponsor	Liquidia Technologies, Inc.
Condition(s)	Raynaud's Phenomenon Secondary to Systemic Sclerosis
Phase	PHASE2
Listed sites	0

Patient-friendly overview of this study: eichor.com/study/NCT07748000.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07748000 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →